Avadel Pharmaceuticals PLC at Oppenheimer Healthcare Conference (Virtual) Transcript
Great. Well, thanks, everyone, for joining today on day three of the Oppenheimer healthcare conference. Still virtual but hopefully we're kind of on the back end of that side. So, I'm Frank Brisebois; I'm one of the biotech analysts at the firm. It's my pleasure to introduce Avadel Pharmaceuticals. The ticker is AVDL. We do cover the stock at an outperform rating at the firm, and they are focused on narcolepsy.
Here -- we'll go over it in depth, but the story is it's a once nightly sodium oxybate [trying] to enter an already established blockbuster market, but they did have a PDUFA date. And I don't think we can have this chat without talking about it, Greg. And I'm sorry; I'm sure you've talked about it plenty. But more questions to come here.
So, the PDUFA date was October 15 and we've been waiting on the FDA. And it seems like nothing really on Avadel's side much here. But we'll go into the details of what's going on there. They also just announced their earnings this morning and it seems like they had recent FDA interaction. So, all
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
